Synonym
Pluracidomycin; SF 2103 A
IUPAC/Chemical Name
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 7-oxo-3-sulfo-6-(1-(sulfooxy)ethyl)-, (5R-(5alpha,6beta(S*)))-
InChi Key
KSUVJVOKUIADCL-RPDRRWSUSA-N
InChi Code
InChI=1S/C9H11NO10S2/c1-3(20-22(17,18)19)6-4-2-5(21(14,15)16)7(9(12)13)10(4)8(6)11/h3-4,6H,2H2,1H3,(H,12,13)(H,14,15,16)(H,17,18,19)/t3-,4+,6-/m0/s1
SMILES Code
O=C(C(N12)=C(S(=O)(O)=O)C[C@]2([H])[C@H]([C@@H](OS(=O)(O)=O)C)C1=O)O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
357.30
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Tsuji N, Kobayashi M, Terui Y, Matsumoto K, Takahashi Y, Kondo E. Pluracidomycin A2, a new carbapenem bearing a sulfinic acid, and other minor pluracidomycins. J Antibiot (Tokyo). 1985 Feb;38(2):270-4. PubMed PMID: 3997673.
2: Tsuji N, Nagashima K, Kobayashi M, Terui Y, Matsumoto K, Kondo E. The structures of pluracidomycins, new carbapenem antibiotics. J Antibiot (Tokyo). 1982 Apr;35(4):536-40. PubMed PMID: 7096210.
3: Yoshida T, Kazuno Y, Shomura T, Murata S, Inouye S, Ito T. Therapeutic effect of SF-2103A, a novel carbapenem antibiotic, in combination with cefotaxime, cefoperazone and other cephalosporins. J Antibiot (Tokyo). 1986 Jul;39(7):956-65. PubMed PMID: 3531130.
4: Niwa T, Yoshida T, Tamura A, Kazuno Y, Inouye S, Ito T, Kojima M. In vitro evaluation of SF-2103A, a novel carbapenem antibiotic, as a beta-lactamase inhibitor. J Antibiot (Tokyo). 1986 Jul;39(7):943-55. PubMed PMID: 3019978.
5: Ito T, Ezaki N, Ohba K, Amano S, Kondo Y, Miyado HS, Shomura T, Sezaki M, Niwa T, Kojima M, Inouye S, Yamada Y, Nida T. A novel beta-lactamase inhibitor, SF-2103 A produced by a Streptomyces. J Antibiot (Tokyo). 1982 Apr;35(4):533-5. PubMed PMID: 6980216.
6: Yamaguchi A, Hirata T, Sawai T. Novel carbapenem derivative SF2103A: studies on the mode of beta-lactamase inactivation. Antimicrob Agents Chemother. 1984 Mar;25(3):348-53. PubMed PMID: 6372682; PubMed Central PMCID: PMC185515.
